Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which promises results in 30 minutes—for myself.